Progress DNDI-6148, an oxaborole compound, through clinical development for the treatment of leishmaniasis
current phase of drug development
updated 29 Feb 2020
DNDi’s screening of Anacor’s library of drug compounds from the oxaborole class, followed by focused medicinal chemistry efforts, led to the discovery of a number of analogues showing efficacy in animal models of sleeping
sickness, Chagas, and leishmaniasis.
DNDI-6148 has emerged as a promising lead candidate for visceral leishmaniasis and cutaneous leishmaniasis and by the end of 2015 studies including exploratory toxicology necessary for possible progression to preclinical development had been successfully completed.
Get our latest news, personal stories, research articles, and job opportunities.